PPF ("Pmg Partners Funds") - PMG Helix Biotechnology Fund R USD

PPF Global Biotech invests primarily in North American biotechnology companies, dedicating about 38% to oncology and hematology, 16% to autoimmune and rheumatology sectors, 11% to genetic drugs and vaccines, 10% to infectious diseases, and 9% to neuro and neurodegenerative areas. The fund also includes smaller portions in rare diseases, endocrinology, diagnostics, and analytics services. By focusing on innovative small and medium-sized firms with strong drug pipelines, PPF Global Biotech aims for long-term growth through cutting-edge medical advancements.